Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)
Technology appraisal
Reference number: TA1132
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.